USClinicalTrials.govClinical trialPhase 1/2Recruiting
Safety of HRX215 in Patients After Minor and Major Liver Resection
Official record
- Identifier
NCT06638502- Recruiting locations
countries
United StatesFranceGermanyIsraelSpain- Interventions studied
- HRX215 capsulesPlacebo capsules
- Lead sponsor
- HepaRegeniX GmbH
- Target enrolment
- 80 participants
- Study type
- INTERVENTIONAL
- Phase
- Phase 1/2
- Status
- Recruiting
- First posted
- Oct 15, 2024
- Last updated on the registry
- Sep 14, 2026
- Age
- 18 Years – 75 Years
- Sex
- ALL
- Study contact
- The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.
- Eligibility criteria
Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.
Inclusion Criteria: * Participants with liver metastases originating from colon carcinoma planned for R0-intended hepatectomy for colorectal liver metastases * Part 1 only: stable participants within 1-3 days after minor liver resection, normal non-tumor liver parenchyma * Part 2 and 3 only: Major liver resection. * Low estimated risk for post-hepatectomy liver failure PHLF Further inclusion criteria apply Exclusion Criteria: * Liver Cirrhosis * Preoperative presence of clinical ascites * Any other hepatobiliary cancer * BMI \>35 kg/m2 * ASA Score \>4 * Peritoneal carcinomatosis Further exclusion criteria apply
- Indexed under
- Liver Cancer